Regeneron Pharmaceuticals Inc (REGN)

Current ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total current assets	US$ in thousands	18,660,900	19,333,600	19,081,600	18,871,500	19,479,200	18,634,800	16,923,000	16,909,200	15,884,100	15,428,600	15,529,900	14,306,000	14,014,900	13,775,400	13,337,600	10,055,100	9,779,100	9,097,600	7,860,200	8,644,100
Total current liabilities	US$ in thousands	3,944,300	3,661,000	3,508,600	3,580,900	3,423,400	3,598,600	3,104,400	3,100,100	3,141,300	2,879,200	3,033,900	3,007,600	3,932,500	3,714,800	3,732,400	3,217,800	2,697,400	2,337,800	3,702,400	2,055,200
Current ratio		4.73	5.28	5.44	5.27	5.69	5.18	5.45	5.45	5.06	5.36	5.12	4.76	3.56	3.71	3.57	3.12	3.63	3.89	2.12	4.21

December 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $18,660,900K ÷ $3,944,300K
= 4.73

Regeneron Pharmaceuticals Inc's current ratio has shown a consistently healthy trend over the reported periods, ranging between 2.12 and 5.69. The current ratio measures the company's ability to meet its short-term obligations with its current assets.

The current ratio increased steadily from 2.12 as of June 30, 2020, to 5.69 as of December 31, 2023, indicating improvement in the company's liquidity and ability to cover its short-term liabilities.

It should be noted that a higher current ratio generally suggests a stronger liquidity position. However, a very high current ratio may indicate an inefficient use of assets, as excess liquidity could be invested for better returns.

Regeneron Pharmaceuticals Inc's current ratio peaked at 5.69 by the end of December 31, 2023, before slightly decreasing to 4.73 by the end of December 31, 2024. Overall, the company's current ratio reflects strong short-term financial health and liquidity, providing a cushion to meet its obligations as they come due.